Novartis signs on to support Malaria No More’s Power of One campaign to stride towards a future without malaria
25 April 2013 | By Novartis
"We believe that this innovative campaign will help speed malaria elimination..."
List view / Grid view
25 April 2013 | By Novartis
"We believe that this innovative campaign will help speed malaria elimination..."
24 April 2013 | By Novartis
Novartis announced the compensation for the incoming Chairman of the Board, starting August 1, 2013...
23 April 2013 | By Novartis
Results from the 64-week SPARK study...
19 April 2013 | By Novartis
A new beta blocker-free, fixed-combination therapy for glaucoma patients...
1 April 2013 | By Novartis
Novartis has never been granted an original patent for Glivec in India...
26 March 2013 | By Novartis
Latest global patient-use data...
21 March 2013 | By Novartis
New data presented...
18 March 2013 | By Novartis
Alcon announces EU approval of Jetrea®, first and only eye drug to treat sight-threatening vitreomacular traction and macular hole...
15 March 2013 | By Novartis
First filing for LDK378 anticipated in early 2014...
13 March 2013 | By Novartis
New data will be presented...
1 March 2013 | By Novartis
Novartis announced that the European Commission has approved llaris (canakinumab, ACZ885)...
28 February 2013 | By Novartis
Novartis today announced that it has launched an effort to eliminate rheumatic heart disease in Zambia in collaboration with the Lusaka...
24 February 2013 | By Novartis
Late-breaking results from ASTERIA II...
15 February 2013 | By Novartis
The FDA has approved Zortress®...
23 January 2013 | By Novartis
Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia...